Stock Analysis on Net
Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Johnson & Johnson, common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019
Loans and notes payable 2.06 2.33 6.10 9.17 6.82 2.53 2.42 2.41 2.07 2.12 1.80 1.94 1.50 2.97 3.37 1.41 0.76 1.48 1.11 1.14
Accounts payable 5.75 5.03 5.45 5.06 6.25 5.80 5.49 5.22 6.07 5.00 4.93 4.93 5.43 4.13 4.27 4.78 5.42 4.82 4.46 4.61
Accrued liabilities 6.09 6.08 5.53 5.72 6.11 6.83 7.09 7.29 7.48 7.71 5.94 7.66 7.99 5.64 5.64 5.41 6.16 5.79 5.35 5.30
Accrued rebates, returns and promotions 9.55 9.52 8.18 7.54 7.69 8.01 7.57 7.27 6.64 7.08 7.06 6.91 6.58 7.28 7.44 7.49 6.90 7.06 6.73 6.35
Accrued compensation and employee related obligations 2.38 2.01 1.60 1.14 1.78 1.72 1.53 1.18 1.97 1.76 1.54 1.19 1.99 1.76 1.46 1.40 2.13 1.86 1.48 1.32
Accrued taxes on income 1.79 1.75 1.40 2.18 1.14 1.13 1.11 0.96 0.61 1.21 0.68 1.09 0.80 0.98 1.03 1.25 1.44 1.61 1.10 0.68
Current liabilities 27.62% 26.72% 28.26% 30.81% 29.78% 26.01% 25.22% 24.33% 24.85% 24.86% 21.95% 23.72% 24.30% 22.76% 23.22% 21.73% 22.80% 22.61% 20.21% 19.40%
Long-term debt, excluding current portion 15.45 15.69 17.69 17.82 14.35 15.76 15.92 16.18 16.47 16.81 17.18 17.54 18.66 19.15 15.82 16.38 16.80 17.31 17.86 18.44
Deferred taxes on income 1.91 1.58 1.89 2.25 3.40 2.82 2.82 3.60 4.11 3.99 5.11 3.77 4.12 3.29 3.49 3.72 3.78 4.20 4.98 4.93
Employee related obligations 4.27 3.42 3.37 3.40 3.61 4.77 4.81 4.90 4.89 5.67 5.88 6.09 6.16 5.97 6.57 6.79 6.76 6.32 6.39 6.60
Long-term taxes payable 1.72 1.53 1.32 2.19 2.30 2.38 2.34 3.22 3.14 3.22 3.24 3.81 3.75 3.95 4.16 4.77 4.72 4.82 4.86 5.38
Other liabilities 8.00 8.17 7.61 7.36 5.57 5.66 5.92 5.89 5.87 6.24 7.21 6.92 6.83 7.12 6.97 7.06 7.44 7.32 6.51 5.95
Non-current liabilities 31.33% 30.39% 31.88% 33.03% 29.23% 31.40% 31.82% 33.78% 34.49% 35.93% 38.62% 38.13% 39.52% 39.47% 37.02% 38.73% 39.49% 39.96% 40.60% 41.30%
Total liabilities 58.96% 57.11% 60.14% 63.84% 59.01% 57.40% 57.04% 58.11% 59.33% 60.79% 60.56% 61.85% 63.82% 62.23% 60.24% 60.46% 62.30% 62.57% 60.81% 60.70%
Common stock, par value $1.00 per share 1.86 1.88 1.63 1.59 1.67 1.78 1.76 1.75 1.71 1.74 1.77 1.81 1.78 1.83 1.97 2.01 1.98 2.01 2.01 2.08
Accumulated other comprehensive loss -7.48 -5.29 -6.85 -6.44 -6.92 -8.73 -7.79 -7.71 -7.17 -8.60 -8.56 -8.88 -8.71 -8.75 -9.81 -10.48 -10.07 -9.99 -9.65 -10.34
Retained earnings and Additional paid-in capital 91.81 91.86 67.50 63.56 68.50 73.04 71.02 69.74 67.61 67.56 68.10 67.52 65.12 67.27 71.91 72.83 70.16 70.24 70.79 71.09
Common stock held in treasury, at cost -45.16 -45.55 -23.07 -22.55 -22.25 -23.50 -22.02 -21.89 -21.48 -21.49 -21.87 -22.29 -22.01 -22.58 -24.31 -24.83 -24.36 -24.83 -23.97 -23.53
Total Johnson & Johnson shareholders’ equity 41.04% 42.89% 39.20% 36.16% 40.99% 42.60% 42.96% 41.89% 40.67% 39.21% 39.44% 38.15% 36.18% 37.77% 39.76% 39.54% 37.70% 37.43% 39.19% 39.30%
Equity attributable to non-controlling interest 0.00 0.00 0.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total equity 41.04% 42.89% 39.86% 36.16% 40.99% 42.60% 42.96% 41.89% 40.67% 39.21% 39.44% 38.15% 36.18% 37.77% 39.76% 39.54% 37.70% 37.43% 39.19% 39.30%
Total liabilities and shareholders’ equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Johnson & Johnson current liabilities as a percentage of total liabilities and shareholders’ equity decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Johnson & Johnson non-current liabilities as a percentage of total liabilities and shareholders’ equity decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Johnson & Johnson total liabilities as a percentage of total liabilities and shareholders’ equity decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.
Total Johnson & Johnson shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Johnson & Johnson total Johnson & Johnson shareholders’ equity as a percentage of total liabilities and shareholders’ equity increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.